Thomas A. Macek

2.5k total citations · 1 hit paper
35 papers, 1.3k citations indexed

About

Thomas A. Macek is a scholar working on Psychiatry and Mental health, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Thomas A. Macek has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 13 papers in Molecular Biology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Thomas A. Macek's work include Bipolar Disorder and Treatment (11 papers), Schizophrenia research and treatment (9 papers) and Receptor Mechanisms and Signaling (8 papers). Thomas A. Macek is often cited by papers focused on Bipolar Disorder and Treatment (11 papers), Schizophrenia research and treatment (9 papers) and Receptor Mechanisms and Signaling (8 papers). Thomas A. Macek collaborates with scholars based in United States, Canada and United Kingdom. Thomas A. Macek's co-authors include P. Jeffrey Conn, Miriam Cohen, John Panagides, Larry Alphs, Roger S. McIntyre, Jun Zhao, Hervé Schaffhauser, Danny G. Winder, Robert W. Gereau and Zhaohui Cai and has published in prestigious journals such as Nature Medicine, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas A. Macek

35 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

2022 168 citations Kevin A. Strauss, Michelle A. Farrar et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas A. Macek United States	17	481	446	383	163	146	35	1.3k
Sitra Tauscher‐Wisniewski United States	17	505 1.0×	417 0.9×	319 0.8×	327 2.0×	160 1.1×	36	1.3k
Emin Özyurt Türkiye	18	213 0.4×	345 0.8×	430 1.1×	77 0.5×	104 0.7×	39	971
Sebastian Ivens Germany	12	494 1.0×	669 1.5×	787 2.1×	53 0.3×	90 0.6×	16	1.7k
Hilarie C. Tomasiewicz United States	9	361 0.8×	91 0.2×	570 1.5×	76 0.5×	105 0.7×	10	915
Ming‐Chi Lai Taiwan	19	259 0.5×	230 0.5×	399 1.0×	40 0.2×	92 0.6×	41	1.1k
Candice E. Crocker Canada	19	290 0.6×	201 0.5×	307 0.8×	29 0.2×	70 0.5×	54	1.1k
Andreas Brunklaus United Kingdom	22	560 1.2×	1.0k 2.2×	358 0.9×	64 0.4×	112 0.8×	47	1.8k
Lothar Burghaus Germany	20	292 0.6×	185 0.4×	385 1.0×	132 0.8×	258 1.8×	61	1.5k
Julien Praline France	17	219 0.5×	236 0.5×	161 0.4×	267 1.6×	111 0.8×	49	976
Tommaso Piccoli Italy	20	241 0.5×	126 0.3×	216 0.6×	145 0.9×	286 2.0×	46	1.2k

Countries citing papers authored by Thomas A. Macek

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Macek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Macek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Macek more than expected).

Fields of papers citing papers by Thomas A. Macek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Macek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Macek. The network helps show where Thomas A. Macek may publish in the future.

Co-authorship network of co-authors of Thomas A. Macek

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Macek. A scholar is included among the top collaborators of Thomas A. Macek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Macek. Thomas A. Macek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pandina, Gahan, Joan Busner, Lucas Kempf, et al.. (2024). Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.. PubMed. 21(1-3). 52–60. 3 indexed citations

Finkel, Richard S., Basil T. Darras, Jerry R. Mendell, et al.. (2023). Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG). Journal of Neuromuscular Diseases. 10(3). 389–404. 30 indexed citations

Strauss, Kevin A., Michelle A. Farrar, Francesco Muntoni, et al.. (2022). Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nature Medicine. 28(7). 1381–1389. 168 indexed citations breakdown →

Taieb, V., et al.. (2019). PRO35 ECONOMIC BURDEN OF CARE IMPOSED ON PATIENTS WITH RETT SYNDROME: A SYSTEMATIC LITERATURE REVIEW. Value in Health. 22. S341–S341. 1 indexed citations

Leonard, Helen, Tim A. Benke, Pamela S. Diener, et al.. (2019). Establishing Clinical Trial Readiness of the Rett Syndrome Hand Function Measure (P1.6-034). Neurology. 92(15_supplement). 2 indexed citations

Yurgelun‐Todd, Deborah, Perry F. Renshaw, Paul Goldsmith, Tolga Uz, & Thomas A. Macek. (2019). A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects. Psychopharmacology. 237(2). 317–328. 9 indexed citations

Day, John, Claudia A. Chiriboga, Thomas O. Crawford, et al.. (2019). P.349Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy Type 1 (SMA1): Pivotal phase 3 study (STR1VE) update. Neuromuscular Disorders. 29. S183–S183. 2 indexed citations

Macek, Thomas A., Maggie McCue, Xinxin Dong, et al.. (2018). A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophrenia Research. 204. 289–294. 43 indexed citations

Mahableshwarkar, Atul R., Joseph R. Calabrese, Thomas A. Macek, et al.. (2017). Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. Journal of Affective Disorders. 221. 275–282. 19 indexed citations

10.

Goldsmith, Paul, Maggie McCue, Max Tsai, et al.. (2017). A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. Drugs in R&D. 17(4). 631–643. 13 indexed citations

11.

Wickwire, Emerson M., Scott G. Williams, Thomas Roth, et al.. (2016). Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group. Neurotherapeutics. 13(2). 403–417. 115 indexed citations

12.

Tsai, Max, et al.. (2016). A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Psychopharmacology. 233(21-22). 3787–3795. 16 indexed citations

13.

Takano, Akihiro, Per Stenkrona, В. А. Степанов, et al.. (2016). A human [ 11 C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. NeuroImage. 141. 10–17. 22 indexed citations

14.

McIntyre, Roger S., Miriam Cohen, Jun Zhao, et al.. (2010). Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study. Journal of Affective Disorders. 126(3). 358–365. 68 indexed citations

15.

McIntyre, Roger S., Miriam Cohen, Jun Zhao, et al.. (2010). Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 122(1-2). 27–38. 110 indexed citations

16.

McIntyre, Roger S., Miriam Cohen, Jun Zhao, et al.. (2009). Asenapine versus olanzapine in acute mania: a double‐blind extension study. Bipolar Disorders. 11(8). 815–826. 76 indexed citations

17.

McIntyre, Roger S., Miriam Cohen, Jun Zhao, et al.. (2009). A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders. 11(7). 673–686. 131 indexed citations

18.

Undevia, Samir D., Hedy L. Kindler, Linda Janisch, et al.. (2004). A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Annals of Oncology. 15(11). 1705–1711. 60 indexed citations

19.

Sorensen, Scott D., Thomas A. Macek, Zhaohui Cai, Julie A. Saugstad, & P. Jeffrey Conn. (2002). Dissociation of Protein Kinase-Mediated Regulation of Metabotropic Glutamate Receptor 7 (mGluR7) Interactions with Calmodulin and Regulation of mGluR7 Function. Molecular Pharmacology. 61(6). 1303–1312. 25 indexed citations

20.

Macek, Thomas A., Hervé Schaffhauser, & P. Jeffrey Conn. (1999). Activation of PKC Disrupts Presynaptic Inhibition by Group II and Group III Metabotropic Glutamate Receptors and Uncouples the Receptor from GTP‐Binding Proteins. Annals of the New York Academy of Sciences. 868(1). 554–557. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact